title: Expression of claudin, paxillin and FRA-1 in non-nodular breast lesions in association with microcalcifications.
abstract: OBJECTIVE
  The possible role of adhesion molecules in early breast carcinogenesis has been shown in the literature. We aimed to analyze early adhesion imbalances in non-nodular breast lesions and their association with precursor lesions, in order to ascertain whether these alterations exist and contribute towards early carcinogenesis.
  
  
  METHODS
  Retrospective cross-sectional study based on medical records at a private radiological clinic in São Paulo, Brazil.
  
  
  METHODS
  We retrospectively reviewed the medical records of all consecutive women attended between August 2006 and July 2007 who presented mammographic evidence of breast microcalcifications classified as Breast Imaging Reporting and Data System Atlas (BI-RADS) type 4. These women underwent stereotaxic biopsy. Clinical, radiological and pathological data were collected, and immunohistochemical assays searched for claudin, paxillin, FRA-1 and HER-2.
  
  
  RESULTS
  Over this period, 127 patients were evaluated. Previous BI-RADS diagnoses showed that 69 cases were in category 4A, 47 in 4B and 11 in 4C. Morphological assessment showed benign entities in 86.5%. Most of the benign lesions showed preserved claudin expression, associated with paxillin (P < 0.001). Paxillin and HER-2 expressions were correlated. FRA-1 expression was also strongly associated with HER-2 expression (P < 0.001).
  
  
  CONCLUSIONS
  Although already present in smaller amounts, imbalance of adhesion molecules is not necessarily prevalent in non-nodular breast lesions. Since FRA-1 expression reached statistically significant correlations with radiological and morphological diagnoses and HER-2 status, it may have a predictive role in this setting.
authors: Departments of Pathology, Radiology and Morphology, Universidade Federal de São Paulo Unifesp, São Paulo, Brazil. kandelman@terra.com.br
authors: José David
authors: JD
authors: Kandelman
authors: Angela Flávia Logullo
authors: AF
authors: Waitzberg
authors: Jacob
authors: J
authors: Szejnfeld
authors: Ricardo Luiz
authors: RL
authors: Smith
mesh_terms: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology; D002114:Calcinosis / Q000378:metabolism* / Q000473:pathology; D057167:Claudins / Q000032:analysis*; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000378:metabolism / Q000473:pathology; D051419:Paxillin / Q000032:analysis*; D011230:Precancerous Conditions / Q000737:chemistry / Q000473:pathology; D016760:Proto-Oncogene Proteins c-fos / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000099169:Fos-Related Antigen 1
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D057167:Claudins; D051419:Paxillin; D016760:Proto-Oncogene Proteins c-fos; D018719:Erb-b2 Receptor Tyrosine Kinases; D000099169:Fos-Related Antigen 1; C508053:ERBB2 protein, human
references: BMC Cancer. 2007 Jan 25;7:17
references: 17254320
references: J Cell Biol. 2000 Apr 3;149(1):13-6
references: 10747082
references: Histopathology. 2011 Mar;58(4):617-25
references: 21371080
references: J Natl Cancer Inst. 2004 Apr 21;96(8):616-20
references: 15100339
references: Endocr Relat Cancer. 2001 Mar;8(1):47-61
references: 11350726
references: Am J Surg Pathol. 2009 Apr;33(4):496-504
references: 19047897
references: Physiol Rev. 2004 Oct;84(4):1315-39
references: 15383653
references: J Urol. 2002 Apr;167(4):1836-43
references: 11912444
references: Oncogene. 2010 Feb 4;29(5):662-73
references: 19966854
references: BMC Cancer. 2006 Jul 12;6:186
references: 16836752
references: N Engl J Med. 1985 Jan 17;312(3):146-51
references: 3965932
references: Cancer Res. 2009 May 15;69(10):4116-24
references: 19435916
references: BMC Cancer. 2006 Dec 28;6:298
references: 17192200
references: Hum Pathol. 2006 Jan;37(1):9-15
references: 16360410
references: Oncogene. 2001 Oct 1;20(44):6459-72
references: 11607845
references: Oncogene. 2005 Feb 17;24(8):1434-44
references: 15608675
references: Breast Cancer Res Treat. 1993 Nov;28(2):157-66
references: 8173068
references: Eur J Gynaecol Oncol. 2011;32(2):156-9
references: 21614903
references: Breast J. 2007 Mar-Apr;13(2):130-9
references: 17319853
references: Virchows Arch. 2009 Jun;454(6):647-56
references: 19387682
references: J Cell Biol. 1992 Nov;119(4):893-903
references: 1385444
references: Oncogene. 2003 Aug 7;22(32):5045-54
references: 12902987
references: Cancer. 1993 Feb 15;71(4):1258-65
references: 8435803
references: Breast Cancer Res. 2008;10(5):R91
references: 18954444
references: Mol Cell Biol. 1998 Dec;18(12):7095-105
references: 9819396
references: Histopathology. 2010 Aug;57(2):171-92
references: 20500230
references: Histopathology. 1984 Nov;8(6):963-75
references: 6098550
references: J Mol Signal. 2008 Jan 02;3:1
references: 18171471
references: Int J Cancer. 2009 May 1;124(9):2088-97
references: 19142967